A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema

Journal of the American Academy of Dermatology

Volumn 51, Issue 2, 2004, Pages 120-123

  Horn, Keren B ^a   Horn, Meyer A ^a   Swan, James ^a   Singhal, Seema ^a   Guitart, Joan ^a  

^a Joliet Oncology and Hematology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN LAMBDA CHAIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; HUMAN TISSUE; MALE; PARAPROTEINEMIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCLEROMYXEDEMA; SKIN BIOPSY; TREATMENT OUTCOME; ANAMNESIS; DISEASE COURSE; ELECTROPHORESIS; LABORATORY TEST; SIDE EFFECT; BIOPSY; DIFFUSE SCLERODERMA; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SKIN;

BIOPSY; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SKIN;

EID: 3242740460     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.03.023     Document Type: Article

References (20)

1. Chanda J.J. Melphalan therapy in the treatment of scleromyxedema. Arch Dermatol. 116:1980;862-863
2. Harris A.O., Altman A.R., Tschen J.A., Wolf J.E. Scleromyxedema. Int J Dermatol. 28:1989;661-667
3. Godby A., Bergstresser P.R., Chaker B., Pandya A.G. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 38:1998;289-294
4. MacFarlane A.W., Davenport A., Verbov J.L., Goldsmith H.J. Scleromyxedema: successful treatment with plasma exchange and immunosuppression. Br J Dermatol. 117:1987;653-657
5. Berkson M., Lazarus G.S., Uberti-Benz M., Rook A.H. Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol. 25:1991;724
6. Lister R.K., Jolles S., Whittaker S., Black C., Forgacs I., Cramp M., et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 43:2000;403-408
7. Tschen J.A., Chang J.R. Scleromyxedema: Treatment with interferon alfa. J Am Acad Dermatol. 40:1999;303-307
8. Feasel A.M., Donato M.S., Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol. 137:2001;1071-1072
9. Dubreiuilh W. Fibromes miliaires folliculaires: sclerodermie consecutive. Ann Dermatol Syph. 37:1906;569-572
10. Reitmann K. Uber eine Eigenartige, der Sklerodermie Nahestehende Affektion. Arch Dermatol Syph. 92:1908;417-424
11. Rongioletti F., Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 44:2001;273-281
12. Degos R., Civatte J., Clauvel J.P., Danon F. Anomalies globuliniques dans les mucinoses cutanées. Bull Soci Fr Dermatol Syphiligr. 77:1970;579
13. Jackson E.M., English J.C. Diffuse cutaneous mucinoses. Dermatol Clin. 20:2002;493-501
14. Yaron M., Yaron I., Brenner S. Lichen myxedematosus (Scleromyxedema) serum stimulates hyaluronic acid and prostaglandin production by human fibroblasts. Rheumatalogy. 12:1985;171-175
15. Ferrarini M., Helfrich D.J., Walker E.R., Medsger T.A. Jr., Whiteside T.L. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatal. 16:1989;837-841
16. Harper R.A., Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science. 199:1978;545-547
17. Bata-Csorgo Z., Husz S., Foldes M., Korom I., Molnar K., Morvay M., et al. Scleromyxedema. J Am Acad Dermatol. 41:1999;343-346
18. Rayson D., Lust J.A., Duncan A., Su W.P. Scleromyxedema: a complete response to prednisone. Mayo Clin Proc. 74:1999;481-484
19. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. 94:1998;557-572
20. Silvestri M., Sabatini F., Scarso L., Cordone A., Dasic G., Rossi G.A. Fluticasone propionate downregulates nasal fibroblast functions involved in airway inflammation and remodeling. Int Arch Allergy Immunol. 128:2002;51-58